Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-05
2011-07-05
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388850, C530S391100, C530S391300, C530S391700
Reexamination Certificate
active
07973138
ABSTRACT:
The present invention relates to the use of VEGF antagonists and a novel anti-α5β1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-α5β1 antibodies and methods of making and using them.
REFERENCES:
patent: 5766857 (1998-06-01), Ruoslahti et al.
patent: 5981478 (1999-11-01), Ruoslahti et al.
patent: 6242577 (2001-06-01), Ruoslahti et al.
patent: 6852318 (2005-02-01), Varner
patent: 7056506 (2006-06-01), Varner
patent: 7067619 (2006-06-01), Ruoslahti et al.
patent: 7276589 (2007-10-01), Ramakrishnan
patent: 7285268 (2007-10-01), Ramakrishnan
patent: 7311911 (2007-12-01), Varner
patent: 2005/0260210 (2005-11-01), Ramakrishnan et al.
patent: 2006/0008415 (2006-01-01), Kaisheva et al.
patent: 2008/0026033 (2008-01-01), Ramakrishnan
patent: 2008/0026458 (2008-01-01), Ramakrishnan
patent: 2008/0113898 (2008-05-01), Varner
patent: 2008/0188641 (2008-08-01), Varner
patent: 2008/0233108 (2008-09-01), Varner
patent: 2008/0260732 (2008-10-01), Ramakrishnan
patent: 2009/0220504 (2009-09-01), Chuntharapai et al.
patent: 1075277 (2009-02-01), None
patent: WO95/14714 (1995-06-01), None
patent: WO99/58139 (1999-11-01), None
patent: WO2004/056308 (2004-07-01), None
patent: WO2005/092073 (2005-10-01), None
patent: WO2006/004736 (2006-01-01), None
patent: WO2007/060408 (2007-05-01), None
patent: WO2007/060409 (2007-05-01), None
patent: WO2007/091046 (2007-08-01), None
patent: WO2008/060645 (2008-05-01), None
Bauer, Jeffrey Steven, “The Funtional Role of Integrins in Cell Adhesion, Motility and Differentiation (Integrins, Extracellular Matrix)”Dissertation Abstracts International54/06-B:3009 (1993).
Burrows et al., “Fine mapping of inhibitory anti-alpha5 monoclonal antibody epitopes that differentially affect integrin-ligand binding”The Biochemical Journal(XP002485037) 344(2):527-533 (Dec. 1, 1999).
Chunmeng, S. et al., “Effects of Dermal Multipotent Cell Transplantation on Skin Wound Healing”The Journal of Surgical Research(XP002495102) 121(1):13-19 (Sep. 2004).
International Search Report, received in corresponding PCT Application No. PCT/US2008/077622, dated Feb. 18, 2009.
Written Opinion received in corresponding International Application No. PCT/US2008/077622, dated Feb. 18, 2009.
du Manoir, et al., “Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts”Clinical Cancer Research, The American Association for Cancer Research(XP002384468) 12(3) :904-916 (Feb. 1, 2006).
Economopoulou, M. et al., “Inhibition of pathologic retinal neovascularization by alpha-defensins”Blood1 (XP002495156) 106(12):3831-3838 (Dec. 1, 2005).
Eming et al., “Regulation of angiogenesis: Wound healing as a model”Progress in Histochemistry and Cytochemistry;42:115-170 (Jun. 21, 2007).
Kim et al., “Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1with the Central Cell-Binding Domain of Fibronectin”American Journal of Pathology156(4) :1345-1362 (Apr. 2000).
Mould et al., “Defining the Topology of Integrin Alpha5beta1-Fibronectin Interactions Using Inhibitory Anti-alpha5 and Anti-beta1 Monoclonal Antibodies”The Journal of Biological Chemistry(XP002485038) 272(28) :17283-17292 (Jul. 11, 1997).
Muether, P. et al., “Integrin alpha5beta1-inhibiting small molecule reduces corneal neovascularisation”Database Biosis [online], Biosciences Information Services(Database accession No. PREV200600052329) 46:460 (May 1, 2005).
Newton et al., “Inhibition of experimental metastasis of human breast carcinoma cells in athymic nude mice by anti-α5β1fibronectin receptor integrin antibodies”International Journal of Oncology6:1063-1070 (Feb. 23, 1995).
Orecchia, et al., “Vascular endothelial growth factor receptor-1 is deposited in the extracelluar matrix by endothelial cells and is a ligand for the alpha5beta1 integrin”Journal of Cell Science, Cambridge University Press, London (XP002468572) 116(17) :3479-3489 (Sep. 1, 2003).
Pan et al., “Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth”Cell Press(XP-002504811)11:53-67 (Jan. 2007).
Ramakrishnan et al., “Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent”Journal of Experimental Therapeutics and Oncology, Rapid Science Publishers, London, GB. (XP008081487) 5(4) :273-286 (Oct. 6, 2005).
Schreiner et al., “Defective Vasculature in Fibronectin-Receptor-Deficient CHO Cell Tumors in Nude Mice”International Journal of Cancer55:436-441 (Mar. 26, 1993).
Shibata et al., “Fibronectin Secretion from Human Peritoneal Tissue Induces Mr92,000 Type IV Collagenase Expression and Invasion in Ovarion Cancer Cell Lines”Cancer Research57:5416-5420 (Dec. 1, 1997).
Sone,, H. et al., “Neutralization of Vascular Endothelial Growth Factor Prevents Collagen-Induced Arthritis and Ameliorates Established Disease in Mice”Biochemical and Biophysical Research Communications(XP008041534) 281(2) :562-568 (Feb. 23, 2001).
Tanaka, R. et al., “Elastic Plasma-Protein-Film Blended with Platelet-Releasate Accelerates Healing of Diabetic Mouse Skin Wounds”Blood(XP008095745) 106(11) :583A (Nov. 1, 2005).
Thorpe et al., “Selective killing of proliferating vascular endothelial cells by an anti-fibronectin receptor immunotoxin” (Abstract), 1991.
Baluk et al., “Cellular Abnormalities of Blood Vessels as Targets in Cancer”Current Opinion in Genetics&Development15:102-111 (2005).
Humphries et al., “Dual functionality of the anti-beta1 integrin antibody, 12G10, exemplifies agonistic signalling from the ligand binding pocket of integrin adhesion receptors”Journal of Biological Chemistry280(11):10234-10243 (Mar. 18, 2005)
Liang Wei-Ching
Plowman Gregory D.
Wu Yan
Ye Weilan
Duffy Brad
Genentech Inc.
Morrison & Foerster / LLP
Yu Misook
LandOfFree
Antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2709280